Rituxan and Cardiotoxicity - a phase IV clinical study of FDA data

Summary:

Cardiotoxicity is reported as a side effect among people who take Rituxan (rituximab), especially for people who are male, 10-19 old, also take Cyclophosphamide, and have Lymphoma.

The phase IV clinical study analyzes which people have Cardiotoxicity when taking Rituxan. It is created by eHealthMe based on reports of 64,282 people who have side effects when taking Rituxan from the FDA, and is updated regularly.

What is Rituxan?

Rituxan has active ingredients of rituximab. It is often used in rheumatoid arthritis. eHealthMe is studying from 64,791 Rituxan users. Check the latest studies of Rituxan.

What is Cardiotoxicity?

Cardiotoxicity (damage to the heart muscle) is found to be associated with 386 drugs and 511 conditions by eHealthMe. Check the latest studies of Cardiotoxicity.

On Jul, 20, 2026

64,282 people reported to have side effects when taking Rituxan.
Among them, 14 people (0.02%) have Cardiotoxicity.

Among these 14 people:

What is the gender of people who have Cardiotoxicity when taking Rituxan? *

female: 22.22 %
male: 77.78 %

What is the age of people who have Cardiotoxicity when taking Rituxan? *

What are other drugs people take besides Rituxan? *

Cyclophosphamide: 4 people, 28.57%
Prednisone: 2 people, 14.29%
Prednisolone: 2 people, 14.29%
Dexamethasone: 2 people, 14.29%
Methotrexate: 1 person, 7.14%
Gemzar: 1 person, 7.14%
Enoxaparin Sodium: 1 person, 7.14%
Doxorubicin Hydrochloride: 1 person, 7.14%
Cisplatin: 1 person, 7.14%
Bortezomib: 1 person, 7.14%

What are other side effects people have besides Cardiotoxicity? *

Skin Discoloration - Bluish (bluish colour of skin): 2 people, 14.29%
Sinus Tachycardia (a heart rhythm with elevated rate of impulses originating from the sinoatrial node): 2 people, 14.29%
Pulmonary Toxicity (side effects on the lungs): 2 people, 14.29%
Pericardial Effusion (fluid around the heart): 2 people, 14.29%
Chills (felling of cold): 2 people, 14.29%
Weight Increased: 1 person, 7.14%
Drug Ineffective: 1 person, 7.14%
Blood Albumin Decreased: 1 person, 7.14%
Blood Pressure Systolic Increased: 1 person, 7.14%
Cardiomyopathy (weakening of the heart muscle): 1 person, 7.14%

What are the existing conditions these people have? *

Lymphoma (cancer that begins in immune system cells): 4 people, 28.57%
Mantle Cell Lymphoma (cancer of lymphocytes, a type of white blood cell): 2 people, 14.29%
Diffuse Large B-Cell Lymphoma Refractory (cancer of b cells, a type of white blood cell-relapsed): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Rituxan and have Cardiotoxicity?

- Check whether Cardiotoxicity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rituxan:

Rituxan (64,791 reports)

Cardiotoxicity treatments and more:

Cardiotoxicity (8,120 reports)

Browse all side effects of Rituxan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Cardiotoxicity:

Cardiotoxicity (386 drugs)

Browse all the conditions that are associated with Cardiotoxicity:

Cardiotoxicity (511 conditions)

Related publications that referenced our studies

Alam, S., Illo, C., Ma, Y. T., & Punia, P. , "Gemcitabine-induced cardiotoxicity in patients receiving adjuvant chemotherapy for pancreatic cancer: a case series", Case reports in oncology, 2018 Jan .
Alam, S., Illo, C., Ma, Y. T., & Punia, P. , "Gemcitabine-induced cardiotoxicity in patients receiving adjuvant chemotherapy for pancreatic cancer: a case series", Case reports in oncology, 2018 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on rituximab (the active ingredients of Rituxan) and Rituxan (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.